ICCM Announces FDA Approval of ChoICE Post-Market Study for ProSense Cryoablation in Low-Risk Breast Cancer, Enrolls 400 Patients Across 30 Sites, $4K Facility Reimbursement
IceCure Medical Ltd. Ordinary Shares · Now $0.20
Post-detection moves
1h
—
1d
—
3d
—
7d
—
30d
—
Get alerts like this in real time
Push notifications the moment a signal fires. No spam, no crypto, no fluff.
Download for iOS